Multiple Sclerosis Resource Centre
  • Home
  • MSRC Grand Opening 30/05/12
  • About MS
  • MSRC Services
  • Get Involved
  • MS Research News
  • MSRC Groups
  • Useful Resources
  • Welcome To Josephs Court, MS Centre Of Excellence
  • Advertising
  • Best Bet Diet Group
  • E-Newsletter
  • Contact Us
  • Investor in People
    You are here : Home » MS Research News » New Discoveries » Antagonist compounds

    Antagonist compounds

    A A A
    [Print this page]

    Share |

    Antagonist compounds have potential application in multiple sclerosis

    Idera Logo

    Idera Pharmaceuticals, Inc. announced the publication of studies on the chemistry of novel compounds that have been shown to act as antagonists for Toll-like Receptors (TLR) 7 and 9. These antagonist candidates have potential application in autoimmune and inflammatory diseases. The paper
    entitled "Oligodeoxyribonucleotide-Based Antagonists for Toll-Like Receptors 7 and 9" is published in the Journal of Medicinal Chemistry (December 2008, online ahead of print) and is authored by Daqing Wang, Ph.D., Lakshmi Bhagat, Ph.D., Dong Yu, Ph.D., Fu-Gang Zhu, Ph.D., Jimmy Tang, M.S., Ekambar Kandimalla, Ph.D., and Sudhir Agrawal, D.Phil., all of Idera.

    "These novel antagonist candidates have been created through our ongoing
    structure-activity relationship studies of oligonucleotides, through which we
    have also identified agonists of TLR7, 8 and 9," said Sudhir Agrawal, D.Phil., Chief Executive Officer and Chief Scientific Officer. "We have evaluated selected antagonist candidates in preclinical models of lupus, rheumatoid arthritis, multiple sclerosis, psoriasis, and colitis, and studies continue in additional preclinical models of autoimmune and inflammatory diseases."

    "Based on encouraging results in preclinical models, we are conducting
    preclinical development studies with our lead TLR antagonist drug candidate, IMO-3100, for an intended Investigational New Drug application,"
    said Tim Sullivan, Ph.D., Vice President of Development Programs. "Members of our Autoimmune Disease Scientific Advisory Board are assisting us in the clinical development strategy for IMO-3100 and other antagonist candidates in autoimmune and inflammatory diseases."

    About IMO-3100

    IMO-3100 is an antagonist drug candidate currently undergoing preclinical
    development studies for an intended Investigational New Drug application.
    Idera`s antagonists of Toll-like Receptors (TLR) are based on synthetic DNA and have been created through extensive structure-activity relationship studies.

    IMO-3100 has been shown in preclinical assays to suppress immune responses mediated through TLR7 and TLR9. IMO-3100 has been studied in preclinical models of lupus, rheumatoid arthritis, multiple sclerosis, psoriasis, and colitis.

    Evaluation of our TLR antagonists in additional preclinical models of autoimmune and inflammatory diseases is in progress.

    Source: Idera Pharmaceuticals, Inc.(05/01/09)

    Related Items
    Abnormal Liver Tests and MS
    Aluminium and Multiple Sclerosis
    Antibodies, B Cells,T-Cell Activation, Immune Response
    Apolipoprotein D
    Bacteria & MS
    Biomarkers and MicroRNA
    Blood tests
    Bone Marrow Cells and MS Treatment
    Bowmann-Birk Inhibitor Concentrate (BBIC)
    Brain Atrophy, Lesion Loads, White and Grey Matter
    Brain Inflammation
    Brain Iron Deposits
    Calcium Binding Proteins
    Cerebro-Spinal Fluid & Spinal Cord
    Chronic Cerebrospinal Venous Insufficiency (CCSVI)
    CXCL1, 7, 12
    Cytokines & Chemokines
    Dendritic Cells
    Estrogen Receptors
    Fibrinogen, Mac-1 and Microglia
    Histamine and MS
    Hormones And MS Research
    Infections and Multiple Sclerosis Relapses
    JAK-STAT inhibitors
    Kallikrein 6
    Lipids & MS
    Medical Imaging
    Mycoplasmas And Bacteria
    N-acetylglucosamine (GlcNAc) & Glucosamine
    Natural Interferon Beta
    Natural Killer Cells
    Nerve and Brain Cell Research
    Olig 1 Gene Discovery
    Oligodendrocytes and Astrocytes
    Pesticides and Multiple Sclerosis
    Plasma Exchange
    Potential Viral Causes of MS
    Recombinant Human Erythropoietin
    Regeneration Research
    RNA and RNAi
    Synthetic Small Molecules
    Tetanus Vaccine and Possible MS Protection
    The Blood Brain Barrier
    Tremors And MS
    Uric Acid
    Urinary Problems
    Vascular Function And MS
    Vision and MS

    Did you find this information useful? Would you like to comment on this page? Let us know what you think! We welcome all comments and feedback on any aspect of our website - please click here to contact us.